Granting immunity to FOP and catching heterotopic ossification in the Act

Seminars in Cell and Developmental Biology

Volumn 49, Issue , 2016, Pages 30-36

  Kaplan, Frederick S ^a   Pignolo, Robert J ^a   Shore, Eileen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Activin A; ACVR1; Bone morphogenetic protein (BMP); Bone morphogenetic protein signaling; Fibrodysplasia ossificans progressiva (FOP); Heterotopic ossification; Innate immune system; Toll like receptor (TLR)

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; MUTANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ACVR1 PROTEIN, HUMAN;

DISEASE EXACERBATION; GAIN OF FUNCTION MUTATION; HETEROTOPIC OSSIFICATION; HETEROZYGOSITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; MISSENSE MUTATION; NONHUMAN; OSSIFYING MYOSITIS; PATHOPHYSIOLOGY; PERINATAL PERIOD; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING; ANIMAL; GENETICS; IMMUNOLOGY; PHYSIOLOGY;

ACTIVIN RECEPTORS, TYPE I; ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEINS; HUMANS; IMMUNITY, INNATE; MUTATION, MISSENSE; MYOSITIS OSSIFICANS; OSSIFICATION, HETEROTOPIC; SIGNAL TRANSDUCTION;

EID: 84958104294     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.12.013     Document Type: Review

References (93)

1. Shore E.M., Kaplan F.S. Inherited human diseases of heterotopic bone formation. Nat. Rev. Rheumatol. 2010, 6:518-527.
2. Kaplan F.S., Tabas J., Gannon F.H., Finkel G., Hahn G.V., Zasloff M.A. The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. J. Bone. Joint Surg. 1993, 75-A:220-230.
3. Kaplan F.S., Shore E.M., Gupta R., Billings P.C., Glaser D.L., Pignolo R.J., Graf D., Kamoun M. Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway. Clin. Rev. Bone Miner. Metab. 2005, 3:189-193.
4. Kaplan F.S., Pignolo R.J., Shore E.M. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev. 2009, 20:399-407.
5. Hatsell S.J., Idone V., Wolken D.M., Huang L., Kim H.J., Wang L., Wen X., Nannuru K.C., Jimenez J., Xie L., Das N., Makhoul G., Chernomorsky R., D'Ambrosio D., Corpina R.A., Schoenherr C.J., Feeley K., Yu P.B., Yancopoulos G.D., Murphy A.J., Economides A.N. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med. Sep 2 2015, 7(303). 303ra137.
6. Hino K., Ikeya M., Horigome K., Matsumoto Y., Ebise H., Nishio M., Sekiguchi K., Shibata M., Nagata S., Matsuda S., Toguchida J. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. PNAS 2015, 112:15438-15443.
7. Aleman-Muench G.R., Soldevila G. When versatility matters: activins/inhibins as key regulators of immunity. Immunol. Cell Biol. 2012, 90:137-148.
8. Kaplan F.S., Glaser D.L., Shore E.M., Deirmengian G.K., Gupta R., Delai P., Morhart R., Smith R., Le Merrer M., Rogers J.G., Connor J.M., Kitterman J.A. The phenotype of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 2005, 3:183-188.
9. Hüning I., Gillessen-Kaesbach G. Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation. Mol. Syndromol. 2014, 5:201-211.
10. Cohen R.B., Hahn G.V., Tabas J., Peeper J., Levitz C.L., Sando A., Sando N., Zasloff M., Kaplan F.S. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. J. Bone Joint Surg. 1993, 75-A:215-219.
11. Rocke D.M., Zasloff M., Peeper J., Cohen R.B., Kaplan F.S. Age and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 1994, 301:243-248.
12. Pignolo R.J., Bedford-Gay C., Liljesthröm M., Durbin-Johnson B.P., Shore E.M., Rocke D.M., Kaplan F.S. The natural history of flare-ups in Fibrodysplasia Ossificans Progressiva (FOP): a comprehensive global assessment. J. Bone Miner. Res. 2015, 10.1002/jbmr.2728.
13. Schaffer A.A., Kaplan F.S., Tracy M.R., O'Brien M.L., Dormans J.P., Shore E.M., Harland R.M., Kusumi K. Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome. Spine 2005, 30:1379-1385.
14. Deirmengian G.K., Hebela N.M., O'Connell M., Glaser D.L., Shore E.M., Kaplan F.S. Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J. Bone Joint Surg. Am. 2008, 90:366-374.
15. Levy C.E., Lash A.T., Janoff H.B., Kaplan F.S. Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am. J. Audiol. 1999, 8:29-33.
16. Shore E.M., Feldman G.J., Xu M., Kaplan F.S. The genetics of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 2005, 3:201-204.
17. Kitterman J.A., Kantanie S., Rocke D.M., Kaplan F.S. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005, 116:654-661.
18. Kaplan F.S., Xu M., Glaser D.L., Collins F., Connor M., Kitterman J., Sillence D., Zackai E., Ravitsky V., Zasloff M., Ganguly A., Shore E.M. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 2008, 121:e1295-e1300.
19. Kaplan F.S., McCluskey W., Hahn G., Tabas J., Muenke M., Zasloff M.A. Genetic transmission of fibrodysplasia ossificans progressiva. J. Bone Joint Surg. 1993, 75-A:1214-1220.
20. Kussmaul W.G., Esmail A.N., Sagar Y., Ross J., Gregory S., Kaplan F.S. Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 1998, 346:104-109.
21. Kaplan F.S., Glaser D.L. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 2005, 3:213-216.
22. Kaplan F.S., Zasloff M.A., Kitterman J.A., Shore E.M., Hong C.C., Rocke D.M. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J. Bone Joint Surg. Am. 2010, 92:686-691.
23. Kaplan F.S., LeMerrer M., Glaser D.L., Pignolo R.J., Goldsby R.E., Kitterman J.A., Groppe J., Shore E.M. Fibrodysplasia ossificans progressiva. Best Pract. Res. Clin. Rheumatol. 2008, 22:191-205.
24. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clinical Proceedings of International Clinical Consortium on FOP, 4 2011, 1-100. The International Clinical Consortium on FOP. F.S. Kaplan, E.M. Shore, R.J. Pignolo (Eds.).
25. Pignolo R.J., Shore E.M., Kaplan F.S. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J. Rare Dis. 2011, 6:80.
26. Pignolo R.J., Shore E.M., Kaplan F.S. Fibrodysplasia ossificans progressiva: diagnosis management, and therapeutic horizons. Emerging concepts in pediatric bone disease. Pediatr. Endocrinol. Rev 2013, 10(S-2):437-448.
27. Kaplan F.S., Pignolo R.J., Shore E.M. From mysteries to medicines: drug development for fibrodysplasia ossificans progressiva. Expert Opin. Orphan Drugs 2013, 1:637-649.
28. Shore E.M., Xu M., Feldman G.J., Fenstermacher D.A., Cho T.-J., Choi I.H., Connor J.M., Delai P., Glaser D.L., Le Merrer M., Morhart R., Rogers J.G., Smith R., Triffitt J.T., Urtizberea J.A., Zasloff M., Brown M.A., Kaplan F.S. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 2006, 38:525-527.
29. Kaplan F.S., Xu M., Seemann P., Connor J.M., Glaser D.L., Carroll L., Delai P., Fastnacht-Urban E., Forman S.J., Gillessen-Kaesbach G., Hoover-Fong J., Köster B., Pauli R.M., Reardon W., Zaidi S.-A., Zasloff M., Morhart R., Mundlos S., Groppe J., Shore E.M. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 2009, 30:379-390.
30. Chaikuad A., Alfano I., Kerr G., Sanvitale C.E., Boergermann J.H., Triffitt J.T., von Delft F., Knapp S., Knaus P., Bullock A.N. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J. Biol. Chem. 2012, 287:36990-369998.
31. Groppe J.C., Shore E.M., Kaplan F.S. Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin. Orthop. Rel. Res. 2007, 462:87-92.
32. Shen Q., Little S.C., Xu M., Haupt J., Ast C., Katagiri T., Mundlos S., Seemann P., Kaplan F.S., Mullins M.C., Shore E.M. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J. Clin. Invest. 2009, 119:3462-3472.
33. Song G.A., Kim H.J., Woo K.M., Baek J.H., Kim G.S., Choi J.Y., Ryoo H.M. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J. Biol. Chem. 2010, 285:22542-22553.
34. van Dinther M., Visser N., de Gorter D.J., Doorn J., Goumans M.J., de Boer J., ten Dijke P. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J. Bone Miner. Res. 2010, 25:1208-1215.
35. Kaplan F.S., Seemann P., Haupt J., Xu M., Mullins M., Shore E.M. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor that causes fibrodysplasia ossificans progressiva. Methods Enzymol. 2010, 484:357-373.
36. Shafritz A.B., Shore E.M., Gannon F.H., Zasloff M.A., Taub R., Muenke M., Kaplan F.S. Over-expression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N. Engl. J. Med. 1996, 335:555-561.
37. Gannon F.H., Kaplan F.S., Olmsted E., Finkel G., Zasloff M.A., Shore E.M. Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum. Pathol. 1997, 28:339-343.
38. Ahn J., Serrano de la Peña L., Shore E.M., Kaplan F.S. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J. Bone Joint Surg. 2003, 85-A:667-674.
39. Serrano de la Peña L., Billings P.C., Fiori J.L., Ahn J., Shore E.M., Kaplan F.S. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J. Bone Miner. Res. 2005, 20:1168-1176.
40. Fiori J.L., Billings P.C., Serrano de la Peña L., Kaplan F.S., Shore E.M. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J. Bone Miner. Res. 2006, 21:902-909.
41. Billings P.C., Fiori J.L., Bentwood J.L., O'Connell M.P., Jiao X., Nussbaum B., Caron R.J., Shore E.M., Kaplan F.S. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 2008, 23:305-313.
42. Fukuda T., Kohda M., Kanomata K., Nojima J., Nakamura A., Kamizono J., Noguchi Y., Iwakiri K., Kondo T., Kurose J., Endo K.I., Awakura T., Fukushi J., Nakashima Y., Chiyonobu T., Kawara A., Nishida Y., Wada I., Akita M., Komori T., Nakayama K., Nanba A., Yoda T., Tomoda H., Yu P.B., Shore E.M., Kaplan F.S., Miyazono K., Matsuoka M., Ikebuchi K., Ohtake A., Oda H., Jimi E., Owan I., Okazaki Y., Katagiri T. Constitutively activated ALK2 and increased SMAD 1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J. Biol. Chem. 2009, 284:7149-7156.
43. Culbert A.L., Chakkalakal S.A., Theosmy E.G., Brennan T.A., Kaplan F.S., Shore E.M. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification. Stem Cells 2014, 32:1289-1300.
44. Le V.Q., Wharton K.A. Hyperactive BMP signaling induced by ALK2 (R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva. Dev. Dyn. 2012, 241:200-214.
45. Bagarova J., Vonner A.J., Armstrong K.A., Börgermann J., Lai C.S., Deng D.Y., Beppu H., Alfano I., Filippakopoulos P., Morrell N.W., Bullock A.N., Knaus P., Mishina Y., Yu P.B. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol. Cell. Biol. 2013, 33:2413-2424.
46. Groppe J.C., Wu J., Shore E.M., Kaplan F.S. In vitro analysis of dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 2011, 194:291-295.
47. Wang T., Donahoe P.K. The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front. Biosci. 2004, 9:619-631.
48. Huse M., Chen Y.G., Massagué J., Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999, 96:425-436.
49. Huse M., Muir T.W., Xu L., Chen Y.G., Kuriyan J., Massagué J. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell 2001, 8:671-682.
50. Hong C.C., Yu P.B. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev. 2009, 20:409-418.
51. Twombly V., Bangi E., Le V., Malnic B., Singer M.A., Wharton K.A. Functional analysis of saxophone, the Drosophila gene encoding the BMP type I receptor ortholog of human ALK1/ACVR1 and ACVR1/ALK2. Genetics 2009, 183:563-579.
52. Little S.C., Mullins M.C. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat. Cell Biol. 2009, 11:637-643.
53. Convente M.R., Wang H., Pignolo R.J., Kaplan F.S., Shore E.M. The immunological contribution to heterotopic ossification disorders. Curr. Osteoporos. Res. 2015, 13:116-124.
54. Lanchoney T.F., Cohen R.B., Rocke D.M., Zasloff M.A., Kaplan F.S. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J. Pediatr. 1995, 126:762-764.
55. Luchetti W., Cohen R.B., Hahn G.V., Rocke D.M., Helpin M., Zasloff M., Kaplan F.S. Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1996, 81:21-25.
56. Glaser D.L., Rocke D.M., Kaplan F.S. Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 1998, 346:110-116.
57. Scarlett R.F., Rocke D.M., Kantanie S., Patel J.B., Shore E.M., Kaplan F.S. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva (FOP). Clin. Orthop. Rel. Res. 2004, 423:275-279.
58. Moriatis J.M., Gannon F.H., Shore E.M., Bilker W., Zasloff M.A., Kaplan F.S. Limb swelling in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 1997, 336:247-253.
59. Gannon F.H., Valentine B.A., Shore E.M., Zasloff M.A., Kaplan F.S. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 1998, 346:19-25.
60. Gannon F.H., Glaser D., Caron R., Thompson L.D., Shore E.M., Kaplan F.S. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum. Pathol. 2001, 32:842-848.
61. Hegyi L., Gannon F.H., Glaser D.L., Shore E.M., Kaplan F.S., Shanahan C.M. Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification. J. Pathol. 2003, 201:141-148.
62. Glaser D.L., Economides A.N., Wang L., Liu X., Kimble R.D., Fandl J.P., Wilson J.M., Stahl N., Kaplan F.S., Shore E.M. In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J. Bone Joint Surg. 2003, 85-A:2332-2342.
63. Janoff H.B., Zasloff M.A., Kaplan F.S. Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol. Head Neck Surg. 1996, 114:599-604.
64. Yu P.B., et al. BMP type receptor inhibition reduces heterotopic ossification. Nat. Med. 2008, 14:1363-1369.
65. Kaplan F.S., Glaser D.L., Shore E.M., Pignolo R.J., Xu M., Zhang Y., Senitzer D., Forman S.J., Emerson S.G. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J. Bone Joint Surg. Am. 2007, 89:347-357.
66. Chakkalakal S.A., Zhang D., Culbert A.L., Convente M.R., Caron R.J., Wright A.C., Maidment A.D., Kaplan F.S., Shore E.M. An Acvr1 Knock-in mouse has fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 2012, 27:1746-1756.
67. Kaplan F.S., Chakkalakal S.A., Shore E.M. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis. Model Mech. 2012, 5:756-762.
68. Kan L., Liu Y., McGuire T.L., Berger D.M., Awatramani R.B., Dymecki S.M., Kessler J.A. Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells 2009, 27:150-156.
69. Convente M.R., Yang E., Chakkalakal S.A., Zhang D., Caron R.J., Perrien D.S., Kambayashi T., Kaplan F.S., Shore E.M. Targeted ablation of macrophages and mast cells impairs heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. Abstract 2015.
70. Kan L., Lounev V.Y., Pignolo R.J., Duan L., Liu Y., Stock S.R., McGuire T.L., Lu B., Gerard N.P., Shore E.M., Kaplan F.S., Kessler J.A. Substance P signaling mediates BMP-dependent heterotopic ossification. J. Cell. Biochem. 2011, 112:2759-2772.
71. Salisbury E., Rodenberg E., Sonnet C., Hipp J., Gannon F.H., Vadakkan T.J., Dickinson M.E., Olmsted-Davis E.A., Davis A.R. Sensory nerve induced inflammation contributes to heterotopic ossification. J. Cell. Biochem. 2011, 112:2748-2758.
72. Tracey K.J. Understanding immunity requires more than immunology. Nat. Immunol. 2010, 11:561-564.
73. Nakase T., Nomura S., Yoshikawa H., Hashimoto J., Hirota S., Kitamura Y., Oikawa S., Ono K., Takaoka K. Transient and localized expression of bone morphogenetic protein 4 messenger RNA during fracture healing. J. Bone Miner. Res. 1994, 9:651-659.
74. Clever J.L., Sakai Y., Wang R.A., Schneider D.B. Inefficient skeletal muscle repair in inhibitor of differentiation knockout mice suggests a crucial role for BMP signaling during adult muscle regeneration. Am. J. Physiol. Cell Physiol. 2010, 298:C1087-C1099.
75. Kluk M.W., Ji Y., Shin E.H., Amrani O., Onodera J., Jackson W.M., Nesti L.J. Fibroregulation of mesenchymal progenitor cells by BMP-4 after traumatic muscle injury. J. Orthop. Trauma 2012, 26:693-698.
76. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
77. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
78. Cunningham N.S., Paralkar V., Reddi A.H. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:11740-11744.
79. McCullough K.A., Waits C.A., Garimella R., Tague S.E., Sipe J.B., Anderson H.C. Immunohistochemical localization of bone morphogenetic proteins (BMPs) 2, 4, 6, and 7 during induced heterotopic bone formation. J. Orthop. Res. 2007, 25:465-472.
80. Hong J.H., Lee G.T., Lee J.H., Kwon S.J., Park S.H., Kim S.J., Kim I.Y. Effect of bone morphogenetic protein-6 on macrophages. Immunology 2009, 128(1 Suppl.):e442-e450.
81. Kan L., Hu M., Gomes W.A., Kessler J.A. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. 2004, 165:1107-1110.
82. Kopp E., Medzhitov R., Carothers J., Xiao C., Douglas I., Janeway C.A., Ghosh S. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev. 1999, 13:2059-2071.
83. Xiao C., Shim J.H., Klüppel M., Zhang S.S., Dong C., Flavell R.A., Fu X.Y., Wrana J.L., Hogan B.L., Ghosh S. Ecsit is required for Bmp signaling and mesoderm formation during mouse embryogenesis. Genes Dev. 2003, 17:2933-2949.
84. Moustakas A., Heldin C.H. Ecsit-ement on the crossroads of Toll and BMP signal transduction. Genes Dev. 2003, 17:2855-2859.
85. Wi S.M., Moon G., Kim J., Kim S.T., Shim J.H., Chun E., Lee K.Y. TAK1-ECSIT-TRAF6 complex plays a key role in the TLR4 signal to activate NF-κB. J. Biol. Chem. 2014, 289:35205-35214.
86. Olsen O.E., Wader K.F., Hella H., Mylin A.K., Turesson I., Nesthus I., Waage A., Sundan A., Holien T. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun. Signal 2015, 13:27.
87. Yaden B.C., Wang Y.X., Wilson J.M., Culver A.E., Milner A., Datta-Mannan A., Shetler P., Croy J.E., Dai G., Krishnan V. Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice. Am. J. Pathol. 2014, 184:1152-1166.
88. Lounev V., Ramachandran R., Wosczyna M.N., Yamamoto M., Maidment A.D.A., Shore E.M., Glaser D.L., Goldhamer D.J., Kaplan F.S. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J. Bone Joint Surg. Am. 2009, 91:652-663.
89. Medici D., Shore E.M., Lounev V.Y., Kaplan F.S., Kalluri R., Olsen B.J. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 2010, 16:1400-1406.
90. Fukuda T., Scott G., Komatsu Y., Araya R., Kawano M., Ray M.K., Yamada M., Mishina Y. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis 2006, 44:159-167.
91. Wosczyna M.N., Biswas A.A., Cogswell C.A., Goldhamer D.J. Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J. Bone Miner. Res. 2012, 27:1004-1017.
92. Eltzschig H.K., Carmeliet P. Hypoxia and inflammation. N. Engl. J. Med. 2011, 364:656-665.
93. Maeder T. A few hundred people turned to bone. Atl. Mon. 1998, 281:81-89.